Statin therapy with or without ezetimibe and the progression to diabetes

Journal of Clinical Lipidology

Volumn 10, Issue 2, 2016, Pages 306-313

  Barkas, Fotios ^a   Elisaf, Moses ^a   Liberopoulos, Evangelos ^a   Klouras, Eleftherios ^a   Liamis, George ^a   Rizos, Evangelos C ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Diabetes; Ezetimibe; Glucose; Intensity; Prediabetes; Statin

Indexed keywords

ATORVASTATIN; EZETIMIBE; FLUINDOSTATIN; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DISEASE COURSE; DYSLIPIDEMIA; FAMILY HISTORY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MONOTHERAPY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; BLOOD; CHEMICALLY INDUCED; COMPLICATION; DRUG INTERACTION; DYSLIPIDEMIAS; METABOLISM; MIDDLE AGED; RISK;

BLOOD GLUCOSE; DISEASE PROGRESSION; DRUG INTERACTIONS; DYSLIPIDEMIAS; EZETIMIBE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PREDIABETIC STATE; RISK;

EID: 84951817646     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2015.11.015     Document Type: Article

References (30)

1. European Association for Cardiovascular Prevention & Rehabilitation Z. Reiner, A.L. Catapano, G. De Backer, and et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Eur Heart J 32 2011 1769 1818
2. J. Armitage The safety of statins in clinical practice Lancet 370 2007 1781 1790
3. S.N. Rajpathak, D.J. Kumbhani, J. Crandall, N. Barzilai, M. Alderman, and P.M. Ridker Statin therapy and risk of developing type 2 diabetes: a meta-analysis Diabetes Care 32 2009 1924 1929
4. N. Sattar, D. Preiss, H.M. Murray, and et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 2010 735 742
5. P.M. Ridker, E. Danielson, F.A. Fonseca, and et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
6. P.S. Sever, B. Dahlof, N.R. Poulter, and et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 361 2003 1149 1158
7. T.R. Pedersen, O. Faergeman, J.J. Kastelein, and et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial JAMA 294 2005 2437 2445
8. K.K. Koh, I. Sakuma, and M.J. Quon Differential metabolic effects of distinct statins Atherosclerosis 215 2011 1 8
9. C.R. Dormuth, K.B. Filion, J.M. Paterson, and et al. Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases BMJ 348 2014 g3244
10. D. Preiss, S.R. Seshasai, P. Welsh, and et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis Jama 305 2011 2556 2564
11. B. Zafrir, and M. Jain Lipid-lowering therapies, glucose control and incident diabetes: evidence, mechanisms and clinical implications Cardiovasc Drugs Ther 28 2014 361 377
12. F. Barkas, H. Milionis, M.S. Kostapanos, P.D. Mikhailidis, M. Elisaf, and E. Liberopoulos How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic Curr Med Res Opin 31 2015 221 228
13. Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) European Association for the Study of Diabetes (EASD) L. Ryden, P.J. Grant, S.D. Anker, and et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - summary Diab Vasc Dis Res 11 2014 133 173
14. K.G. Alberti, R.H. Eckel, S.M. Grundy, and et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity Circulation 120 2009 1640 1645
15. N.J. Stone, J.G. Robinson, A.H. Lichtenstein, and et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 129 2014 S1 45
16. A.A. Carter, T. Gomes, X. Camacho, D.N. Juurlink, B.R. Shah, and M.M. Mamdani Risk of incident diabetes among patients treated with statins: population based study BMJ 346 2013 f2610
17. D.D. Waters, J.E. Ho, D.A. DeMicco, and et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials J Am Coll Cardiol 57 2011 1535 1545
18. H. Cederberg, A. Stancakova, N. Yaluri, S. Modi, J. Kuusisto, and M. Laakso Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort Diabetologia 58 2015 1109 1117
19. K.C. Maki, M.R. Dicklin, and S.J. Baum Statins and diabetes Cardiol Clin 33 2015 233 243
20. K.C. Maki, P.M. Ridker, W.V. Brown, S.M. Grundy, N. Sattar The Diabetes Subpanel of the National Lipid Association Expert P An assessment by the Statin Diabetes Safety Task Force: 2014 update J Clin Lipidol 8 2014 S17 S29
21. Z.H. Park, A. Juska, D. Dyakov, and R.V. Patel Statin-associated incident diabetes: a literature review Consult Pharm 29 2014 317 334
22. N.A. Sattar, H. Ginsberg, K. Ray, and et al. The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice Atheroscler Suppl 15 2014 1 15
23. C.P. Cannon, M.A. Blazing, R.P. Giugliano, and et al. Ezetimibe added to statin therapy after acute coronary syndromes N Engl J Med 372 2015 2387 2397
24. P. Goyal, L.I. Igel, K. LaScalea, and W.B. Borden Cardiometabolic impact of non-statin lipid lowering therapies Curr Atheroscler Rep 16 2014 390
25. P.P. Toth, A. Catapano, M. Farnier, and et al. Ezetimibe does not increase fasting glucose levels more than statins alone in non-diabetic hypercholesterolemic patients JACC 65 2015
26. L.A. Leiter, D.J. Betteridge, M. Farnier, and et al. Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials Diabetes Obes Metab 13 2011 615 628
27. I. Saito, K. Azuma, T. Kakikawa, N. Oshima, M.E. Hanson, and A.M. Tershakovec A randomized, double-blind, placebo-controlled study of the effect of ezetimibe on glucose metabolism in subjects with type 2 diabetes mellitus and hypercholesterolemia Lipids Health Dis 14 2015 40
28. M.A. Blazing, D.K. McGuire, C.P. Cannon, and et al. New-onset Diabetes Mellitus in the IMPROVE-IT Trial (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) 2015 ESC congress London 2015
29. A.G. Tabak, C. Herder, W. Rathmann, E.J. Brunner, and M. Kivimaki Prediabetes: a high-risk state for diabetes development Lancet 379 2012 2279 2290
30. V.G. Athyros, V.I. Bouloukos, A.N. Pehlivanidis, and et al. The prevalence of the metabolic syndrome in Greece: the MetS-Greece Multicentre Study Diabetes Obes Metab 7 2005 397 405